Share This Page
aminosalicylic acid resin complex - Profile
✉ Email this page to a colleague
What are the generic sources for aminosalicylic acid resin complex and what is the scope of freedom to operate?
Aminosalicylic acid resin complex
is the generic ingredient in one branded drug marketed by Bristol Myers Squibb and is included in one NDA. Additional information is available in the individual branded drug profile pages.Summary for aminosalicylic acid resin complex
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
US Patents and Regulatory Information for aminosalicylic acid resin complex
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | REZIPAS | aminosalicylic acid resin complex | POWDER;ORAL | 009052-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Investment Scenario, Market Dynamics, and Financial Trajectory for Aminosalicylic Acid Resin Complex
Executive Summary
The aminosalicylic acid resin complex (ASARC) is a niche pharmaceutical compound primarily used in the treatment of tuberculosis and potentially other inflammatory diseases. Despite its specialized application, it presents strategic investment opportunities driven by emerging drug resistance, novel delivery methods, and evolving global TB control policies. This analysis examines the market landscape, supply chain, competitive positioning, regulatory environment, and financial forecasts pertinent to ASARC, offering insights for stakeholders considering R&D, manufacturing, or commercialization investments.
What is the Aminosalicylic Acid Resin Complex?
Definition:
Aminosalicylic acid resin complex is a formulation combining aminosalicylic acid (PAS) with a resin carrier. It enhances drug stability, targeted delivery, and pharmacokinetics, especially for oral TB therapies (WHO, 2020). Its unique properties include sustained release, reduced gastrointestinal irritation, and improved bioavailability.
Mechanism of Action:
PAS disrupts mycobacterial folate synthesis. When complexed with resins, the drug’s release profile aligns with therapeutic needs, optimizing patient adherence and efficacy.
Current Indications:
- Tuberculosis, particularly multidrug-resistant strains (MDR-TB)
- Off-label applications in inflammatory bowel disease (IBD), pending further research
Market Dynamics
Global TB Treatment Market Landscape
| Parameter | Details |
|---|---|
| Market size (2022) | Approx. $22.8 billion (Global TB drugs market, MarketsandMarkets[1]) |
| CAGR (2023-2028) | 4.2% |
| Key regions | Sub-Saharan Africa, Southeast Asia, Eastern Europe, China |
| TB burden (2021) | 10 million new cases, 1.5 million deaths (WHO[2]) |
Demand Drivers and Constraints
| Demand Drivers | Constraints |
|---|---|
| Rising MDR-TB cases necessitating alternative treatments | Limited market penetration outside traditional TB zones |
| Global push for TB elimination targets | High development costs and long approval timelines |
| Advances in drug delivery systems improving treatment compliance | Regulatory hurdles for new formulations |
Competitive Landscape
| Entity | Focus Area | Products/Research |
|---|---|---|
| Global pharmaceutical firms | TB drugs, specialty formulations | Johnson & Johnson, Bayer, GlaxoSmithKline |
| Biotech startups | Novel delivery systems, drug complexations | TRiNi Corporation (experimental formulations) |
| Public-private partnerships | R&D funding, access programs | Stop TB Partnership, Global Fund |
Regulatory Environment
| Frameworks | Implications |
|---|---|
| FDA, EMA approvals | Required for market entry in respective territories |
| WHO prequalification | Enhances access in low-income countries |
| Orphan drug designation | Potential for accelerated approval for niche applications |
Financial Trajectory Forecast
Revenue Projections (2023-2030)
| Year | Projected Revenue ($ million) | Remarks |
|---|---|---|
| 2023 | 200 | Pilot commercialization, initial markets |
| 2024 | 250 | Expansion into regional markets |
| 2025 | 340 | Adoption increases, adoption of new formulations |
| 2026 | 440 | Entry into emerging markets, licensing deals |
| 2027 | 560 | Heightening demand, therapeutic research |
| 2028 | 700 | Market stabilization, new indications |
| 2030 | 900+ | Potential breakthroughs, higher adoption |
Cost Structure
| Cost Component | Approximate % of total expenses | Details |
|---|---|---|
| R&D | 30-40% | Formulation, stability, trials |
| Manufacturing | 20-25% | Resin sourcing, scale-up |
| Regulatory & Compliance | 10-15% | Approvals, quality control |
| Marketing & Distribution | 15-20% | Market penetration, medical education |
Investment Benchmarks
| Fundamental Metrics | Values |
|---|---|
| Typical R&D investment for niche drugs | $50-$150 million over 5-7 years |
| Manufacturing capex | $10-$50 million depending on scale |
| Average time to market | 7-10 years |
Comparative Analysis with Similar Drugs
| Drug | Application | Market Size (2022) | Regulatory Milestones | Notes |
|---|---|---|---|---|
| Rifampicin (RIF) | TB treatment | $1.45B (2020) | WHO-prequalified, global standard | Well-established, high competition |
| Clofazimine | MDR-TB, leprosy | Niche $300M | Regulatory approval in multiple countries | Niche, with potential for combination therapy |
| Novel Resin-based formulations | Emerging TB therapies | Niche, growing | Under clinical development | Represents opportunity for ASARC differentiation |
Investment Considerations
Strengths
- Niche therapeutic application with unmet needs
- Potential for formulation IP (patents on resin complexation)
- Increased demand driven by global MDR-TB trends
Weaknesses
- Long R&D and approval timelines
- Limited market size compared to broad-spectrum drugs
- Regulatory uncertainties, especially for off-label uses
Opportunities
- Collaborations with governments for TB eradication efforts
- Licensing deals with larger pharma for distribution
- Innovation in delivery systems (e.g., inhalation, nanoparticle carriers)
Threats
- Patent expirations on existing aminosalicylic acid formulations
- Regulatory delays, especially in low-income regions
- Competition from next-generation anti-TB agents (e.g., bedaquiline)
Key Market Trends and Future Outlook
| Trend | Impact |
|---|---|
| Shift towards personalized TB therapy | Opens avenues for tailored resin complex formulations |
| Increased funding from global health agencies | Accelerates clinical development and market access |
| Emergence of multi-compound formulations | May influence niche drug sales and competitive positioning |
| Advances in drug delivery technologies | Improves efficacy and patient compliance |
FAQs
1. What are the main drivers for investing in aminosalicylic acid resin complex?
Investment drivers include the rising incidence of MDR-TB, the need for improved drug delivery systems, and the increasing focus of global health initiatives on TB elimination. The potential for patent protection and formulation innovation also offers competitive advantages.
2. How does the regulatory process impact the market entry of ASARC?
Regulatory approval requires demonstrating safety, efficacy, and quality standards, often involving lengthy clinical trials. WHO prequalification can facilitate access in low-income countries, but achieving regulatory milestones in multiple regions involves significant time and resource investment.
3. What are the key market risks associated with ASARC?
Risks include regulatory delays, competitive innovations, limited market size, and dependence on global TB burden trends. Additionally, off-label use and alternative therapies may shift market dynamics.
4. How do global health policies influence the trading prospects of ASARC?
Policies prioritizing TB eradication and subsidies from organizations like the WHO and Global Fund can facilitate market access and drive demand, especially if formulations meet predefined standards for low-resource settings.
5. What strategic partnerships are recommended for maximizing returns?
Partnering with government health agencies, NGOs, and global health organizations can enhance market penetration. Licensing agreements with larger pharmaceutical firms can leverage distribution networks, while collaborations with biotech firms can support formulation innovation.
Key Takeaways
- The aminosalicylic acid resin complex holds niche but strategic importance in MDR-TB treatment and potentially other inflammatory diseases.
- The market size is growing modestly (CAGR of approximately 4.2%), driven by increased global TB control efforts and drug resistance challenges.
- Key factors influencing financial trajectories include regulatory approval timelines, formulation patent protection, and global health funding policies.
- Investment opportunities lie in R&D innovation, formulation patents, and establishing strategic partnerships to accelerate market entry.
- Risks include regulatory delays, competition from novel anti-TB agents, and limited market scope.
References
[1] MarketsandMarkets. "Global Tuberculosis Drugs Market." 2022.
[2] WHO. "Global Tuberculosis Report 2022." World Health Organization.
[3] Gounder, M., et al. “Formulation and Delivery of TB Medications: Review of Emerging Technologies.” Journal of Pharmaceutical Innovation, 2021.
[4] World Health Organization. “Prequalification of Tuberculosis Drugs.” 2020.
[5] Johnson & Johnson, Bayer, GSK Annual Reports. 2022.
More… ↓
